In the News
RadPharm, Inc to Lead Sessions at the 4th Phacilitate Oncology Leaders Forum 2009
Princeton, NJ – October 12, 2009 – RadPharm Inc, a global provider of centralized medical image management services to the bio-pharmaceutical and medical device industries announced today that two key executives will be presenting during the upcoming 4th Phacilitate Oncology Leaders Forum 2009 to be held November 9-11, 2009, in Boston, MA. The conference, to be co-located with the Phacilitate 14th R&D Leaders Forum 2009, brings together senior level R&D and business development executives driving the development and launch of novel cancer therapeutics of all classes.
Dr. Eric S. Perlman, Vice President, Molecular Imaging, RadPharm, will present “Where are the Added Values to Pharma of Current Initiatives Using Imaging in Clinical Trials?” on Tuesday, November 10th at 10:40 am. Dr. Perlman’s presentation will review current initiatives that are investigating imaging as a biomarker and when the output of these initiatives may become incorporated into drug development.
Dr. J. Michael O’Neal, Chief Medical Officer, RadPharm will present “Lessons Learned from Independent Central Review in Registrational Trials”, on Tuesday, November 10th at 3:30 pm. Dr, O’Neal will present case studies and review best practices to overcoming likely challenges faced in the application of medical imaging in registrational trials.
About RadPharm, Inc.
RadPharm, a leading imaging core lab, provides complete image management services to global pharmaceutical, biotechnology and medical device organizations, facilitating successful new drug development. RadPharm employs full-time, board certified, sub-specialty trained radiologists, nuclear physicians and medical oncologists to focus on the Medicine Behind the Image™ and offer global trial sponsors medical expertise, advanced technology and proven operational processes to deliver accurate, timely trial data. RadPharm has supported over 350 clinical trials across more than 60 countries and 5000 unique sites. For further information, visit www.radpharm.com.
|
